PepGen Ltd Total Liabilities
PepGen Ltd total liabilities. Based on the latest financial reports, PepGen Ltd (PEPG) has total liabilities worth $21.86 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PepGen Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of PepGen Ltd (2019–2025)
Total liabilities of PepGen Ltd from 2019 to 2025. This chart illustrates how PepGen Ltd's total liabilities have evolved over time, based on quarterly financial data.
PepGen Ltd Competitors by Total Liabilities
The table below lists competitors of PepGen Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WhiteHorse Finance
NASDAQ:WHF
|
USA | $355.34 Million |
|
Phoenix Asia Holdings Limited Ordinary Shares
NASDAQ:PHOE
|
USA | $2.26 Million |
|
SCHMID Group N.V. Class A Ordinary Shares
NASDAQ:SHMD
|
USA | $157.93 Million |
|
Mayfair Gold Corp
V:MFG
|
Canada | CA$2.84 Million |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA
|
India | Rs5.84 Billion |
|
Ultra Chip
TWO:3141
|
Taiwan | NT$1.24 Billion |
|
Tele2 AB (publ)
ST:TEL2-A
|
Sweden | Skr41.14 Billion |
|
Tavia Acquisition Corp. Ordinary Shares
NASDAQ:TAVI
|
USA | $1.78 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down PepGen Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PepGen Ltd assets under control.
Liquidity & Leverage Metrics
PepGen Ltd Total Liabilities Ratios Explained
PepGen Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PepGen Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PepGen Ltd (2019–2025)
The table below shows the annual total liabilities of PepGen Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $26.46 Million | -17.98% |
| 2024-12-31 | $32.26 Million | -6.84% |
| 2023-12-31 | $34.63 Million | -8.41% |
| 2022-12-31 | $37.81 Million | +258.48% |
| 2021-12-31 | $10.55 Million | +1115.09% |
| 2020-12-31 | $868.00K | +166.26% |
| 2019-12-31 | $326.00K | -- |
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatm… Read more